Categories: BodyInterestPlatform
Reverb is a seed-stage oncology company with a highly differentiated platform approach to cytokine therapy. Its Amplifier™ platform uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines. Instead of using heavily engineered exogenous cytokines to treat diseases, which present challenges such as systemic toxicity and immunogenicity, Reverb’s antibodies redirect endogenous cytokines already in the body to cells of interest.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.02.2025 | Seed | $12M | - |
Mentions in press and media 4
| Date | Title | Description |
| 28.02.2025 | Reverb Therapeutics: A New Dawn in Cytokine Therapy | In the world of biotechnology, innovation is the lifeblood. Reverb Therapeutics, a Vancouver-based company, is making waves with its recent $12 million seed funding. This investment, led by Amplitude Ventures, signals a promising shift in h... |
| 24.02.2025 | Reverb Therapeutics: $12 Million (Seed) Raised To Utilize Cytokine Signaling For Treating Diseases | Reverb Therapeutics, a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, announced it has closed a $12 million financing led by founding investor Amplitude Ventures. And other particip... |
| 19.02.2025 | Reverb Therapeutics Raises USD $12M in Seed Financing | Reverb Therapeutics, a Vancouver, BC, Canada-based a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, raised USD $21M in Seed funding.
The round was led by Amplitude Ventures with par... |
| - | Reverb Therapeutics | “Home | Reverb Therapeutics” |
Reviews 0
